Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division.

Slides:



Advertisements
Similar presentations
Pre Tender Meeting UNICEF Supply Division Copenhagen 10-11th December 2008 Siri Bjornstad Yellow Fever Vaccine Tender
Advertisements

1 |1 | Countries using and planning to introduce IPV July 2014 status report This slide deck provides a summary per country on the status of planning for.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
Vaccine in National Immunization Programme Update March 2015.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV.
World Health Organization
1 |1 | Countries using and planning to introduce IPV.
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
WHO RAP Team: Perspective and Update WORKSHOP ON ANALYZING THE POLIO ERADICATION ENDGAME, Seattle, 1-2 July 2015.
World Health Organization
Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.
1 |1 | Countries using and planning to introduce IPV.
Adverse Events following Immunization (AEFI) Monitoring and Causality Assessment An Overview Department of Disease Control Ministry of Public Health Bureau.
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
Data in WHO HQ as of 09 October 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this.
NVAC W. R. Dowdle. Laboratory Containment of Wild Poliovirus in the United States Phase I National Survey and Inventory Final Report January.
1 |1 | Countries using and planning to introduce IPV.
1 |1 | Countries using and planning to introduce IPV and the global status of bOPV registration Countries using and planning to introduce IPV and the global.
Measles Partnership Meeting Update on Vaccine Supply Washington, 27-28th February 2007 UNICEF Supply Division.
Sustaining Polio Eradication IEAG March 2012 The experience of polio-free countries with importations of WPV: Implications for India.
1 Polio Strategic Plan India Expert Advisory Group July 2011 Impact & prospects at the half-way point.
The changing vaccination landscape and the sources of vaccination data
Data in WHO HQ as of 17 Apr 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this document.
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
Sustaining the gains and reaching milestones on the way towards elimination of measles and rubella 15 September 2015 Dr Peter Strebel, WHO, IVB/EPI.
February 2015 An introduction to the switch from trivalent to bivalent oral polio vaccines 1.
Vaccine in National Immunization Programme Update April 2016.
World Health Organization
Data quality for polio eradication: Accuracy & reliability
Perspective and Update
SAGE 2010 Sampling Distribution
2016 Immunization Coverage Data at Subnational Level
Global Polio Eradication: Current Status, Challenges and Future Directions Steven Wassilak, MD Centers for Disease Control and Prevention, Atlanta APHA.
reporting rate of discarded cases* per 100'000 population**
World Health Organization
Yellow Fever Vaccine Tender
Monthly Distribution of Wild Poliovirus Cases1,
SAGE 2009 Sampling Distribution
06/12/2018 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Sampling Distribution
15/01/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
Monthly Distribution of Wild Poliovirus Cases1,
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
24/02/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Onset of most recent WPV1 Case Number of WPV infected districts
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Countries having introduced HepB vaccine
No new positives this week
05/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Countries Using Mening Vaccine in National Immunization Schedule 2011
- Use same categories as for bar chart below Introduced Without GAVI
Onset of most recent case Number of infected districts
04/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1contacts of positive AFP cases, community, healthy children.
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
16/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
27/08/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
Polio Eradication Progress & Challenges.
World Health Organization
Presentation transcript:

Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division

- Programme status update - Update on OPV contracts for Supply & Demand forecast Additional OPV requirements - IPV update

Wild Poliovirus infected districts*, 03 Jun 2008 – 02 Dec 2008 *Excludes vaccine derived polio virus and virus detected from environmental surveillance. district infected with wild polio virus type 1 district infected with wild polio virus type 3 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved district infected with wild polio virus types 1 and 3 Data in WHO HQ as of 02 Dec 2008

Summary of WPV for 2006 to 2008 WPV cases in 2008 Endemic 1,427 Non-endemic 105

Summary of Wild Polio Virus by Type for 2007 and % - WPV1 40% - WPV3

Programmatic Updates Programme strategy is still to prioritise interruption of WPV1 (due to its higher paralytic rate and propensity to spread to polio free areas) while maintaining control on WPV3 India Effective programme Sub-optimal OPV efficacy in key northern India states Nigeria Sub-optimal campaign quality 60% of children not fully immunised Pakistan/Afghanistan Insecurity which is limiting access to communities Pakistan has very efficient virus transmission which require further operational improvements Non Endemic Countries 5 countries (Angola, Chad, DRC, Niger & Sudan) have persistent transmission > 12 months

Update on OPV contracts for 2009

Projected OPV demand from GPEI, June 2008 and included in the UNICEF RFP document * tOPVmOPV1mOPV3TotaltOPVmOPV1mOPV3Total UNICEF sub total , India Pakistan Total 1, , ,528.2 The requirement presented in the tender included Pakistan and India projected needs to ensure maximum visibility to industry.

UNICEF OPV awards Currently the unawarded quantities equal: tOPV requirements for India and Pakistan for both 2009 and 2010, mOPV3 requirements for India and Pakistan for 2009 ~20million doses of mOPV1 for 2009/10 were reserved for later awards. For 2010 the awarded quantities of OPV were not specified by type in order to retain the flexibility to respond to programme needs. The specific OPV type required will be specified to the relevant manufacturers during 2009, in line with the required timelines. The awards made are not for a any specified geographic destination. Awarded quantities

Supply & Demand Forecast for 2009

tOPV Supply & Demand 2009 Pakistan procuring through UNICEF in Second half 2009 India procuring its own tOPV for their two NIDs in early 2010

mOPV1 Supply & Demand 2009 Now 6 WHO PQ/Recommend Suppliers for mOPV1 Expect to revert to all suppliers about the availability of additional mOPV1 in early 2009

mOPV3 Supply & Demand 2009 Includes expected demand from Pakistan in second half of 2009 Demand may increase as WPV1 cases reduce and Programme moves to interrupting WPV3

Summary of OPV by Type 2000 to 2010

Additional OPV needs for 2009 UNICEF Supply Division

Potential OPV Requirements Additional OPV requirements in the range of 400 million doses for second half of 2009 bi-valent OPV (bOPV - types 1 and 3) Factors influence demand for bOPV Results of the clinical trials expect end March 2009 Epidemiological situation UNICEF and WHO will share with industry potential demand scenarios based on the possible clinical trial outcomes WHO will establish & share regulatory pathways Some guiding principle to bOPV use: bOPV will not replace the role of tOPV in maintain immunity in polio free areas Main potential role will be in areas for co-circulating serotypes 1 & 3 where sub-optimal delivery is a major problem. Not expecting a substantial role in areas of sub-optimal OPV efficacy Possible requirement in second half of 2009, depending on trial result

IPV Update

IPV Supply for 2009 UNICEF regularly procures around 250,000 doses of IPV for OPT (Palestine) IPV for India Potential tool to address sup-optimal efficacy of OPV in certain areas of WUP (India). This approach has also been endorsed by the IEAG, SAGE and ACPE. Rapid market survey in October to assess potential availability. Summary Information shared with GOI and the Programme to inform decision-making. The final decision to go ahead and implement the recommendation is with the GOI. The potential quantities needed are still not confirmed, but will be determined by the final target age range for the activities and the available supply. Indicated quantity between million doses for the first round. If the vaccine is requested through UNICEF, WHO pre-qualified vaccine will be preferred. Acknowledging that delays in issuing a tender might impact on vaccine availability, UNICEF will only proceed upon a request from GOI.

Thank you